标准四联疗法及序贯疗法治疗胃溃疡幽门螺杆菌阳性患者疗效分析

目的对比分析标准四联疗法和序贯疗法治疗胃溃疡H.pylori阳性患者的临床疗效。方法收集重庆三峡中心医院消化内科2012年1月-2013年12月120例胃溃疡H.pylori阳性患者,并随机分为实验组和对照组。其中实验组予以序贯疗法(前5d予以雷贝拉唑肠溶片20 mg+阿莫西林1 000 mg,2次/d,后5 d予以雷贝拉唑肠溶片20 mg+左氧氟沙星200 mg+克拉霉素500mg,2次/d)。对照组予以标准四联疗法(雷贝拉唑肠溶片20 mg+阿莫西林1 000 mg+胶体果胶铋220 mg+克拉霉素500 mg,2次/d)。对比两组患者治疗前及治疗结束4周后的Glasgow评分;对比两组患者治疗结束4周后的H.pylori根除情况(14C呼气试验)及内镜下溃疡治疗有效率。同时对比两组患者治疗期间药物不良反应发生率。结果治疗结束4周后,两组患者的临床症状评分均显著低于治疗前(P0.01),且实验组显著低于对照组(P0.01);两组患者腹痛、腹胀和反酸嗳气症状评分均显著低于治疗前,且实验组显著低于对照组(P0.01);实验组的H.pylori根除率显著高于对照组(P0.05);实验组胃镜下的溃疡愈合总有效率显著高于对照组(P0.05)。两组患者治疗期间不良反应发生率相比,差异无统计学意义(P0.05)。结论序贯疗法在治疗胃溃疡中根除H.pylori,改善患者症状和促进溃疡愈合的疗效优于标准四联疗法,同时不增加不良反应发生率,可以作为胃溃疡H.pylori阳性患者的初治首选方案。     

老年胃溃疡抗幽门螺杆菌治疗的预后观察

目的　 探讨老年人胃溃疡抗幽门螺杆菌 (Hp)治疗后的预后情况。　 方法 　将胃溃疡患者分为老年组及青年组 ,予兰索拉唑 (达克普隆 ) ,阿莫西林 ,甲硝唑抗Hp三联治疗。 4周及 1年后复查胃镜及病理学检查 ,了解溃疡的愈合及Hp根除情况。　 结果　老年组平均年龄 65岁 ,青年组平均年龄 32岁。治疗结束后 ,4周后 2组溃疡愈合率分别为 94%、96% ,1年后分别 78%、87% ,Hp根除率 4周后分别为 83%、86% ,1年后分别 76%、70 %。2组差异无显著性 (P >0 0 5 )。Hp根除患者中 ,2组溃疡愈合率 4周后均为 10 0 % ,1年后分别为 89%、95 % ,Hp未根除患者中 ,2组溃疡愈合率 4周后分别为 67%、75 % ,1年后分别为 42 % ,69%。Hp根除与未根除患者溃疡愈合差异有显著性 (P <0 0 5 )。　 结论　老年人胃溃疡患者于抗Hp治疗后 ,溃疡愈合率及Hp根除率与青年人相仿。根除Hp有利于胃溃疡愈合     

四联疗法根治幽门螺旋杆菌感染疗效分析

目的探讨四联疗法治疗幽门螺杆菌(Hp)所致消化性溃疡和胃炎的疗效。方法将317例消化性溃疡和慢性萎缩性胃炎患者随机分为标准三联疗法组、四联7d组和四联10d组。四联疗法组采用左氧氟沙星+阿莫西林+奥美拉唑+枸橼酸铋钾胶囊,治疗周期分别为7d和10d。三联疗法采用奥美拉唑+克拉霉素+阿莫西林,治疗周期14d。结果采用PP分析法计算Hp根除率三联疗法组为78.43%,四联7d组为85.71%,四联10d组为91.00%,差异有统计学意义(P<0.05);采用ITT分析法计算3组的Hp根除率分别为76.19%、83.33%和87.50%,差异无统计学意义(P>0.05);总有效率分别为81.37%、85.71%和89.00%,差异无统计学意义(P>0.05)。三联疗法、四联7d组和四联10d组的成本-效果比分别为4.12、2.58、3.47,四联7d组与四联10d组相对于标准三联组的增量成本-效果比值分别为-14.11和-0.64。结论四联7d及10d方案均具有较高的Hp根除率,两种方案均为安全、有效、经济的一线治疗方案,符合我国国情,值得临床推广。     

胃复春联合三联疗法治疗幽门螺杆菌阳性胃溃疡临床观察

[目的]观察胃复春联合三联疗法（枸橼酸铋雷尼替丁片、阿莫西林分散片、克拉霉素缓释片）对幽门螺杆菌（Hp）阳性胃溃疡的临床疗效,及对Hp根除率、胃泌素（GAS）、胃动素（MTL）的影响.[方法]将Hp阳性的胃溃疡患者176例随机分为两组,治疗组92例、对照组84例.对照组使用三联疗法,治疗组在对照组基础上加服胃复春;服药10天后,对照组单独口服枸橼酸铋雷尼替丁片4周;治疗组在服用枸橼酸铋雷尼替丁片基础上加服胃复春片4周.观察两组的临床疗效、Hp根除率、胃泌素、胃动素水平.[结果]治疗组总有效率95.65 ％,优于对照组,差异有统计学意义（P＜0.05）;治疗组Hp根除率91.30％,优于对照组,差异有统计学意义（P＜0.05）;治疗组治疗后胃泌素水平低于治疗前水平,亦低于对照组治疗后水平,其差异均有统计学意义（P＜0.05）.[结论]胃复春联合三联疗法抗Hp治疗方案能有效根除幽门螺杆菌,降低胃泌素水平,对幽门螺杆菌阳性胃溃疡能起到较好的治疗效果.     

复方嗜酸乳杆菌在首次根除幽门螺杆菌感染胃溃疡失败补救治疗中的应用

[目的]探讨复方嗜酸乳杆菌在三联根治幽门螺杆菌(Hp)感染胃溃疡失败补救治疗中的应用效果。[方法]随机数字法将150例Hp感染胃溃疡(均经标准三联疗法根除Hp失败)患者分为观察组与对照组,各75例,观察组采取复方嗜酸乳杆菌联合四联疗法干预,对照组则行四联疗法干预,比较2组临床疗效、Hp根除率、不良反应及治疗前后血清炎症相关因子[C反应蛋白(CRP)、白细胞介素(IL)-1、IL-6]变化情况。[结果]观察组治疗总有效率、Hp根除率分别为90.67%、82.67%,均显著高于对照组的77.33%、68.00%(P0.05);与治疗前比较,2组治疗后血清CRP、IL-1、IL-6水平均显著下降(P0.05),且观察组治疗后上述指标均显著低于对照组(P0.05);观察组恶心呕吐、腹泻、便秘发生率均显著低于对照组(P0.05)。[结论]相比单纯四联疗法,加以复方嗜酸乳杆菌能有效提高首次三联疗法根除Hp失败的胃溃疡患者Hp根除率,明显减轻炎症反应及减少不良反应。     

幽门螺杆菌感染并发胃溃疡临床特点及规范治疗探讨

目的对幽门螺杆菌感染并发胃溃疡临床特点及规范治疗进行研究探讨。方法随机抽取2013年2月~2014年4月本院消化内科接诊的96例幽门螺杆菌感染并发胃溃疡患者作为研究对象,按照随机数表法将其分为观察组和对照组,每组各48例,对照组采取胶体果胶铋、阿莫西林、奥美拉唑三联疗法治疗,观察组患者在对照组的基础上加用替硝唑,观察并比较两组患者临床疗效及药物不良反应。结果观察组总有效率为97.9%,Hp根除率95.8%明显高于对照组85.4%,70.8%,复发率10.4%明显低于对照组29.2%,组间比较差异具有统计学意义(P0.05),两组患者不良反应发生率比较差异无统计学意义(P0.05)。结论应用质子泵抑制剂、胃黏膜保护剂和两种抗生素联合治疗Hp感染并发胃溃疡可显著提高临床疗效和Hp根除率,降低复发率,且未增加患者不良反应,值得临床推广应用。     

舒肝解郁胶囊联合四联疗法治疗幽门螺杆菌阳性胃溃疡临床观察

[目的]观察舒肝解郁胶囊联合四联疗法(埃索美拉唑、阿莫西林、胶体果胶铋、克拉霉素)对幽门螺杆菌(Hp)阳性胃溃疡的临床疗效与安全性。[方法]89例Hp阳性胃溃疡患者,随机分为观察组(45例)、对照组(44例)。对照组采用四联疗法治疗2周,然后予以埃索美拉唑抑酸治疗4周;观察组在对照组基础上从第1~6周加用舒肝解郁胶囊2片、2次/d进行治疗。观察2组患者胃泌素浓度(GAS)、胃动素浓度(MTL)、临床症状评分、疗效、Hp根除率及用药不良反应。[结果]经过6周治疗,2组患者GAS浓度、MTL浓度及临床症状评分较治疗前均有显著改善;观察组患者GAS浓度、MTL浓度及临床症状评分均显著低于对照组(P<0.05);观察组治疗总有效率为95.56%、Hp根除率为93.33%,显著高于对照组(P<0.05);观察组不良反应发生率显著低于对照组(P<0.05)。[结论]舒肝解郁胶囊联合四联疗法治疗Hp阳性溃疡相对于四联疗法可更有效缓解患者临床症状、提高溃疡愈合率和Hp根除率,不良反应相对较少,值得推广。     

改良序贯疗法根除老年幽门螺杆菌感染的疗效分析

目的评价含甲磺酸左氧氟沙星的改良序贯疗法对老年幽门螺杆菌(H.pylori)感染患者的根除疗效和安全性。方法收集2017年1月至2018年6月在北京老年医院门诊就诊的老年H.pylori感染良性患者120例,按随机数表法将患者分为改良序贯疗法组(研究组)和铋剂四联疗法组(对照组),各组60例。研究组:先予以埃索美拉唑20 mg+阿莫西林1 000 mg,2次/d,共5 d,再予以埃索美拉唑20 mg+克拉霉素500 mg+甲磺酸左氧氟沙星200 mg,2次/d,共5 d。对照组:埃索美拉唑20 mg+阿莫西林1 000 mg+克拉霉素500 mg+枸橼酸铋钾220 mg,2次/d,共14 d。对H.pylori根除率进行意向性治疗分析(ITT)及符合方案分析(PP),并比较2组患者不良反应发生率。应用成本-效果分析法对2组方案进行经济效益评价。采用SPSS 17.0统计软件分析。组间比较采用t检验或χ~2检验。结果研究组50例根除成功,6例失访;对照组46例根除成功,5例失访,4例未完成治疗。ITT分析:研究组和对照组根除率分别为83.3%(50/60)和76.7%(46/60),差异无统计学意义(χ~2=1.944,P=0.378);PP分析:2组根除率分别为92.6%(50/54)和90.2%(46/51),差异无统计学意义(χ~2=0.192,P=0.463)。研究组患者发生不良反应7例(11.7%),无严重不良反应事件;对照组患者发生不良反应12例(20.0%),4例(6.7%)发生严重不良反应事件而终止治疗。2组患者不良反应(χ~2=1.563,P=0.159)及严重不良反应(χ~2=4.138,P=0.059)发生率比较差异无统计学意义。治疗组与对照组一个疗程费用依次为345.71元和533.71元。按PP分析,治疗组和对照组的成本-效果比(C/E)分别为373.3(345.71/92.6%)和591.7(533.71/90.2%),差异有统计学意义(P0.05);按ITT分析,治疗组和对照组C/E分别为415.0(345.71/83.3%)和695.8(533.71/76.7%),差异亦有统计学意义(P0.05)。结论含甲磺酸左氧氟沙星的改良序贯疗法对老年患者H.pylori有较好的根除效果,可作为根除H.pylori的一种治疗方案。     

治疗的依从性、年龄、性别对胃溃疡患者使用三联7天疗法根除幽门螺杆菌治疗的影响

目的研究胃溃疡患者使用三联7天疗法治疗幽门螺杆菌（Helicobacter pylori,H.pylori）感染的根除率,评估患者依从性、年龄、性别对于此类人群根除H.pylori治疗的影响。方法将经胃镜检查确诊为新发胃溃疡,并经活组织病理学检查明确有H.py-lori感染的1 075例患者纳入研究范围,所有入选患者均接受三联（洛赛克或耐信20 mg/次、2次/天,联合克拉霉素500 mg/次、2次/天,与阿莫西林1 000 mg/次、2次/天）7天疗法行根除H.pylori治疗,之后予以耐信或洛赛克20 mg/次、1次/天、治疗49天。所有入选患者系统治疗完成后6-8周复查胃镜。结果40-59岁与60岁以上人群的胃溃疡患者对治疗的依从性差异无显著性,而40岁以下人群对治疗的依从性较差（P〈0.05）。〈40岁、40-59岁和≥60岁胃溃疡患者的H.pylori根除率分别为61.0%、72.7%和81.9%。〈40岁与40-59岁和≥60岁患者的H.pylori根除率差异有统计学意义（P〈0.05）。不同性别胃溃疡患者的H.pylori根除率差异无显著性（P〉0.05）。结论使用三联7天疗法治疗胃溃疡患者的H.pylori感染,H.pylori的根除率较低,患者对治疗的依从性、年龄是影响胃溃疡患者H.pylori根除率的重要因素,而性别对此无影响。     

Comparison of Helicobacter pylori infection and gastric mucosal histological features of gastric ulcer patients with chronic gastritis patients

AIM: To compare Helicobacter pylori infection and gastric mucosal histological features of gastric ulcer patients with chronic gastritis patients in different age groups and from different biopsy sites. METHODS: The biopsy specimens were taken from the antrum, corpus and upper angulus of gastric ulcer and chronic gastritis patients. Giemsa staining, improved Toluidine-blue staining and H pylori-specific antibody immune staining were performed as appropriate for the histological diagnosis of H pylori infection. Hematoxylin-eosin staining was used for the histological diagnosis of activity of H pylori infection, mucosal inflammation, glandular atrophy and intestinal metaplasia and scored into four grades according to the Updated Sydney System. RESULTS: Total rate of H pylori infection, mucosal inflammation, activity of H pylori infection, glandular atrophy and intestinal metaplasia in 3 839 gastric ulcer patients (78.5%, 97.4%, 82.1%, 61.1% and 64.2%, respectively) were significantly higher than those in 4 102 chronic gastritis patients (55.0%, 90.3%, 56.2%, 36.8%, and 37.0%, respectively, P<0.05). The rate of H pylori colonization of chronic gastritis in <30 years, 31-40 years, 41-50 years, 51-60 years, 61-70 years and >70 years age groups in antrum was 33.3%, 41.7%, 53.6%, 57.3%, 50.7%, 43.5%, respectively; in corpus, it was 32.6%, 41.9%, 53.8%, 60.2%, 58.0%, 54.8%, respectively; in angulus, it was 32.4%, 42.1%, 51.6%, 54.5%, 49.7%, 43.5%, respectively. The rate of H pylori colonization of gastric ulcer in <30 years, 31-40 years, 41-50 years, 51-60 years, 61-70 years and >70 years age groups in antrum was 60.5%, 79.9%, 80.9%, 66.8%, 59.6%, 45.6%, respectively; in corpus, it was 59.7%, 79.6%, 83.6%, 80.1%, 70.6%, 59.1%, respectively; in angulus, it was 61.3%, 77.8%, 75.3%, 68.8%, 59.7%, 45.8%, respectively. The rate of H pylori colonization at antrum was similar to corpus and angulus in patients, below 50 years, with chronic gastritis and in patients, below 40 years, with gastric ulcer. In the other age- groups, the rate of H pylori colonization was highest in corpus, lower in antrum and lowest in angulus (all P<0.05). The rates of glandular atrophy and intestinal metaplasia were higher and earlier in H pylori-positive patients than those without H pylori infection (both P<0.01). In comparison of gastric ulcer patients with chronic gastritis patients, the rate of glandular atrophy and intestinal metaplasia was higher in H pylori-positive patients with gastric ulcer than in H pylori-positive patients with chronic gastritis (both P<0.01); the rate of glandular atrophy and intestinal metaplasia were also higher in H pylori-negative patients with gastric ulcer than in H pylori-negative patients with chronic gastritis (both P<0.01). Both glandular atrophy and intestinal metaplasia were much more commonly identified in the angulus than in the antrum, lowest in corpus (all P<0.01). CONCLUSION: Rate of H pylori infection, glandular atrophy and intestinal metaplasia in gastric ulcer were higher than in chronic gastritis in all-different age -groups. Distribution of H pylori colonization is pangastric in the younger patients. It is highest in corpus, lower in antrum and lowest in angulus in the older age groups. Progression of glandular atrophy and intestinal metaplasia seem to have a key role in the distribution of H pylori colonization. H pylori appears to be the most important risk factor for the development of glandular atrophy and intestinal metaplasia, but it is not the only risk.     

根除幽门螺杆菌对胃溃疡愈合质量及复发的影响研究

目的探讨幽门螺杆菌（Helicobacter pylori，Up）对胃溃疡愈合质量及复发的影响。方法120例坳阳性活动期胃溃疡患者，口服泮托拉唑、阿莫西林、甲硝唑一周后，继续口服泮托美拉唑5周。治疗结束后复查胃镜取病理组织学检查并检测Hp根除情况，对比却根除组与却根除失败组内镜下溃疡愈合形态差异和愈合质量（包括内镜下再生黏膜成熟度和再生黏膜组织学成熟度）。所有患者随诊1年以上了解溃疡复发情况。结果治疗后92例胃溃疡患者月p检测阴性，坳根除率为80．43％；却根除组与跏根除失败组在内镜下愈合率方面的差异无显著性意义（P〉0．05），但两组在再生黏膜成熟度和再生黏膜组织学成熟度方面的差异有显著性意义（P〈0．01）。坳根除组1年溃疡复发率为4．35％，却根除失败组为21．43％，两组差异有显著性意义（P〈0．05）。结论根除Hp可提高胃溃疡的愈合质量，减少溃疡病复发。     

Characteristics of gastric cancer in peptic ulcer patients with Helicobacter pylori infection

AIM:To evaluate the incidence and clinical characteristics of gastric cancer(GC) in peptic ulcer patients with Helicobacter pylori(H.pylori) infection.METHODS:Between January 2003 and December 2013, the medical records of patients diagnosed with GC were retrospectively reviewed.Those with previous gastric ulcer(GU) and H.pylori infection were assigned to the Hp GU-GC group(n = 86) and those with previous duodenal ulcer(DU) disease and H.pylori infection were assigned to the Hp DUGC group(n = 35).The incidence rates of GC in the Hp GU-GC and Hp DU-GC groups were analyzed.Data on demographics(age, gender, peptic ulcer complications and cancer treatment), GC clinical characteristics [location, pathological diagnosis, differentiation, T stage, Lauren's classification, atrophy of surrounding mucosa and intestinal metaplasia(IM)], outcome of eradication therapy for H.pylori infection, esophagogastroduodenoscopy number and the duration until GC onset were reviewed.Univariate and multivariate analyses were performed to identify factors influencing GC development.The relative risk of GC was evaluated using a Cox proportional hazards model.RESULTS:The incidence rates of GC were 3.60%(86/2387) in the Hp GU-GC group and 1.66%(35/2098) in the Hp DU-GC group.The annual incidence was 0.41% in the Hp GU-GC group and 0.11% in the Hp DUGC group.The rates of moderate-to-severe atrophy of the surrounding mucosa and IM were higher in the Hp GU-GC group than in the Hp DU-GC group(86% vs 34.3%, respectively, and 61.6% vs 14.3%, respectively, P 0.05).In the univariate analysis, atrophy of surrounding mucosa, IM and eradication therapy for H.pylori infection were significantly associated with the development of GC(P 0.05).There was no significant difference in the prognosis of GC patients between the Hp GU-GC and Hp DU-GC groups(P = 0.347).The relative risk of GC development in the Hp GUGC group compared to that of the Hp DU-GC group,after correction for age and gender,was 1.71(95%CI:1.09-2.70;P=0.02).CONCLUSION:GU patients with H.pylori infection had higher GC incidence rates and relative risks.Atrophy of surrounding mucosa,IM and eradication therapy were associated with GC.     

胶体果胶铋联合泮托拉唑三联治疗H.pylori阳性胃溃疡的疗效分析

目的观察胶体果胶铋联合泮托拉唑三联对H.pylori阳性胃溃疡的溃疡愈合质量的影响以及根除H.pylori的疗效。方法将经胃镜检查及14C呼气试验确诊的90例H.pylori阳性胃溃疡患者随机分为两组:对照组45例,口服泮托拉唑40 mg bid+左氧氟沙星200 mg bid+阿莫西林1 000 mg bid,连续口服10 d后,停服阿莫西林及左氧氟沙星,继续口服泮托拉唑40 mg qd维持3周;试验组45例,在对照组的基础上加用胶体果胶铋干混悬剂150 mg qid。停药4周后复查14C呼气试验,观察H.pylori根除情况;疗程结束后,胃镜复查评估溃疡愈合情况。结果试验组和对照组H.pylori根除率分别为88.89%、71.11%,两组相比,差异有统计学意义(P0.05);溃疡愈合率分别为86.67%、68.89%,两组相比,差异有统计学意义(P0.05)。试验组溃疡愈合S2期获得率57.78%,显著高于对照组的33.33%(P0.05)。结论胶体果胶铋联合泮托拉唑三联治疗H.pylori阳性胃溃疡是一种高效、简便、安全的临床方案,胶体果胶铋在抗H.pylori、提高溃疡愈合质量上起着重要作用。     

根除老年人消化性溃疡合并幽门螺旋杆菌感染的治疗策略

目的对质子泵抑制剂（PPI）或铋剂三联疗法作为初治方案以及序贯疗法或四联疗法作为补救方案根除老年人消化性溃疡（PUA）合并幽门螺旋杆菌（Hp）感染的疗效进行比较。方法2009年7月至2010年7月间261例胃镜下尿素酶法诊断的PUA合并Hp感染患者,随机采用PPI三联疗法、铋剂三联1周疗法进行根除,观察治疗过程中不良反应发生率。PUA患者经上述抗Hp治疗后继续4周抗溃疡治疗,停药1月后复查胃镜并比较两种方法对Hp根除率及溃疡愈合率的疗效差异。对于首次三联疗法根除Hp失败者,随机应用10日序贯疗法和PPI、铋剂四联1周疗法再次行Hp根除。观察疗程中不良反应发生率,停药1个月后采用”C呼气试验观察Hp根除率。统计分析采用符合方案（PP）群组分析和意向治疗（ITT）群组分析。结果相比于铋剂三联疗法,PPI三联疗法Hp根除率（ITT：77．7％vs62．6％;PP：79．5％v564．1％;P〈0．05）及溃疡愈合率（ITT：78．5％vs64．9％;PP：80．3％vs66．4％;P〈0．05）高,不良反应发生率无明显差异（1TT：10．8％vs16．8％：PP：11．0％vs17．2％;P〉0．05）。对于首次三联疗法失败者以10日序贯疗法补救,Hp根除率较高（ITT：84．6％vJ61．5％;PP：86．8％v563．2％;P〈0．05）,且不良反应发生率较四联疗法低（ITT：12．8％VS35．9％;PP：13．2％VS36．8％;P〈0．05）。结论PPI三联1周疗法进行Hp感染根除可作为PUA患者首选,有较高的溃疡愈合率和Hp根除率;首次根除失败者可优先改用10日序贯疗法进行补救。     

Association of Helicobacter pylori IgA antibodies with the risk of peptic ulcer disease and gastric cancer

AIM: To compare the prevalence of Helicobacter pylori (H pylori) IgG and IgA antibodies between adult subjects, with defined gastric diseases, nondefined gastric disorders and those representing the population. METHODS: Data on H pylori IgG and IgA antibodies, determined by enzyme immunoassay, were analyzed in 3 252 subjects with DGD including 482 patients with gastric ulcer, 882 patients with duodenal ulcer, 1 525 patients with chronic gastritis only and 363 subjects with subsequent gastric cancer, 19 145 patients with NoDg and 4 854 POPUL subjects. The age-adjusted prevalences were calculated for 1-and 20-year age cohorts. RESULTS: The prevalences of IgG antibodies were equally high (89-96%) in all 20-year age cohorts of the DGD groups, whereas the prevalences of IgG antibodies were lower and increased by age in the POPUL and NoDg groups. The prevalences of IgA antibodies were also higher in the DGD groups; among them CA (84-89%) and GU groups (78-91%) showed significantly higher prevalences than DU (68-77%) and CG patients (59-74%) (OR 2.49, 95%CI 1.86-3.34 between the GU and DU groups). In the CA, GU, and DU groups, the IgA prevalences showed only minor variation according to age, while they increased by age in the CG, POPUL, and NoDg groups (P≤0.0001). The IgA response, but not the IgG response, was associated with an increased risk of CA (OR 2.41, 95%CI 1.79-3.53) and GU (OR 2.57, 95%CI 1.95-3.39) in comparison with CG patients. CONCLUSION: An IgA antibody response during H pylori infection is significantly more common in CA and GU patients as compared with CG patients.     

Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients

BACKGROUND: The prevalence of Helicobacter pylori increases with age. However, data regarding the effects of anti-H. pylori treatments in the elderly are very scarce. METHODS: To evaluate the effect of three lansoprazole-based, 7 day, triple-therapy regimens on H. pylori eradication rates, symptomatology, chronic gastritis activity and serological markers of H. pylori infection in elderly subjects, we studied 150 symptomatic patients over 60 years of age with H. pylori-positive duodenal ulcer (DU, n = 34), gastric ulcer (GU, n= 19) or chronic gastritis (CG, n = 97). Patients were consecutively treated with one of the following regimens: (A) lansoprazole (LNS) 30 mg b.i.d. + clarithromycin (CLR) 250 mg b.i.d. + metronidazole (MTR) 250 mg q.i.d.; (B) LNS 30mg b.i.d. + amoxycillin (AMOX) 1 g b.i.d. + MTR 250 mg q.i.d.; and (C) LNS 30 mg b.i.d. + CLR 250 mg b.i.d. + AMOX 1 g b.i.d. RESULTS: Two months after therapy, the eradication rates of the three treatments, expressed using both intention-to-treat and per-protocol analyses were, respectively; group A, 86 and 91.5%; group B, 80 and 87%; group C, 82 and 89.1%. After therapy, a significant reduction in epigastric pain (P<0.001), heartburn (P=0.02), dyspepsia (P<0.001) and vomiting (P< 0.005) was observed independently of the success of H. pylori eradication. A significantly higher percentage of asymptomatic patients were in the GU-DU group than in CG group (87.7 vs 70.0%, P= 0.032). After therapy, 33 subjects still suffered from symptoms. Persistence of symptoms was significantly associated with an endoscopic diagnosis of oesophagitis and not with H. pylori infection. Patients cured of H. pylori infection showed a significant decrease in the histological activity of both antral and body gastritis (P< 0.0001), a significant drop in immunoglobulin (Ig) G anti-H. pylori antibodies (P< 0.0001) and pepsinogen (PG) C (P<0.0001) and an increase in the PGA/PGC ratio (P<0.0001). CONCLUSIONS: The 7 day, lansoprazole-based triple therapy was well tolerated and highly effective in the cure of H. pylori infection, the reduction of symptoms, chronic gastritis activity and serum levels of IgG anti-H. pylori antibodies and PGC. Persistence of symptoms after therapy was significantly higher in CG than GU and DU patients and was significantly associated with oesophagitis.     

Persistence of Helicobacter pylori infection in patients with peptic ulcer perforation

Objective. In patients with perforated peptic ulcer (PPU) the convergence between the high eradication rate of Helicobacter pylori infection and low rates of ulcer relapse after treatment has been associated with reinfection by non-virulent strains. The objective of this study was to evaluate the persistence of infection by virulent H. pylori strains and ulcer recurrence in 33 patients with PPU one year after surgery and antimicrobial treatment. Material and methods. The histological evaluation and molecular detection of H. pylori cagA and ureA genes, vacA allelic types and the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analyses of the glmM gene products from antral mucosa specimens were performed initially, 2–5 months and 1 year after therapy. Results. The density of H. pylori colonization was temporarily decreased (p<0.05) 2–5 months after therapy. After one year, complete eradication was achieved in only 7 patients (23%) at histological examination and recurrent ulcers were found in 3/33 (9%) patients. The vacA s1a allelic type of cagA-positive strains persisted in 19/33 (58%) PPU patients with identical PCR-RFLP fingerprints in 8/9 (89%) of the patients. Conclusions. In PPU patients with a low eradication rate of H. pylori infection after surgical and antimicrobial treatment, the frequent recrudescence of the infection is mostly caused by the persisting virulent strains of the cagA and vacA s1a subtypes. In the 1-year follow-up period the recurrent ulceration can be postponed just by the lowered colonization density of H. pylori after eradicative therapy.